The historical rank and industry rank for CTI BioPharma's Gross Margin % or its related term are showing as below:
CTIC'
s Gross Margin % Range Over the Past 10 Years
Min: 87.96 Med: 97.6 Max: 99.6
Current: 94.11
During the past 13 years, the highestGross Margin % of CTI BioPharma was 99.60%. The lowest was 87.96%. And the median was 97.60%.
CTIC's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.655
vs CTIC: 94.11
CTI BioPharma had a gross margin of 94.92% for the quarter that ended in Mar. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CTI BioPharma was 0.00% per year.
CTI BioPharma Gross Margin % Historical Data
The historical data trend for CTI BioPharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CTI BioPharma's Gross Margin %
For the Biotechnology subindustry, CTI BioPharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTI BioPharma's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CTI BioPharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CTI BioPharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CTI BioPharma had a gross margin of 94.92% for the quarter that ended in Mar. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CTI BioPharma Gross Margin % Related Terms
Thank you for viewing the detailed overview of CTI BioPharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
CTI BioPharma (CTI BioPharma) Business Description
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTIC has been successfully added to your 